Altravax, Inc. Awarded $1.2 Million in Federal Funds for Vaccines for HIV/AIDS

MolecularBreeding™ technology platform offers potential of broader protection

FARGO, N.D.--(BUSINESS WIRE)-- Altravax, Inc. announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH’s National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1. A 2009 report from the United Nations has estimated the total number of people living with AIDS is now at over 30 million. Altravax will use its proprietary MolecularBreeding™ directed evolution technology to create vaccines that provide broad protection against the various strains of HIV-1. The existence of a large number of virus strains and the continued changing nature of the virus is one of the major challenges facing the development of vaccines for HIV/AIDS.

Dr. Robert Whalen, the Chief Scientific Officer at Altravax, is one of the leaders in the development of the MolecularBreeding™ technology platform for use in the vaccine area. “Our past research activities have made significant progress in developing novel vaccine antigens to broadly target the numerous HIV-1 strains and we are pleased that the NIH is continuing to support our research on HIV vaccines," said Dr. Whalen. "This continued federal support is a critical factor in our program to develop a preventative vaccine to combat the AIDS epidemic.”

Altravax also recently received a third NIH SBIR grant for $600,000 to support its research on “Improved Vaccines for Influenza B Virus” to create vaccines that provide broad protection against the two influenza B virus strains that co-circulate each flu season. Including its development of a therapeutic vaccine to treat chronic hepatitis B infection, Altravax is focusing on three areas of major importance for improving human health: hepatitis B, influenza and HIV.

In January 2010, Altravax acquired from Maxygen, Inc. (Nasdaq: MAXY) exclusive rights to the MolecularBreeding™ technology platform for the development of vaccines to infectious diseases.

About Altravax, Inc.

Altravax, Inc. is a privately held biopharmaceutical company with headquarters in Fargo, ND and research laboratories in Sunnyvale, CA. Altravax was founded based on the strength of a proven technology platform that can produce novel vaccine candidates with the potential to protect humans from infectious diseases and improve health globally.



CONTACT:

Arthur Ventures, LLC
Media Contact:
James B. Burgum, 701-232-3521
[email protected]

KEYWORDS:   United States  North America  California  North Dakota

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Clinical Trials  Genetics  Hospitals  Infectious Diseases  Pharmaceutical  Research  Medical Supplies  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.